Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Yu, H. A. [1 ]
Cantero, F. [2 ]
Kim, B. [3 ]
Lee, M. [4 ]
Wu, E. [5 ]
Sternberg, D. W. [6 ]
Janne, P. A. [7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Med Oncol, 1275 York Ave, New York, NY 10021 USA
[2] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[3] Daiichi Sankyo Inc, Clin Sci, Basking Ridge, NJ USA
[4] Daiichi Sankyo Inc, Quantitat Clin Pharmacol, Basking Ridge, NJ USA
[5] Daiichi Sankyo Inc, Biostat, Basking Ridge, NJ USA
[6] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ USA
[7] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1190TiP
引用
收藏
页码：S1092 / S1093
页数：2
相关论文
共 50 条
  • [31] Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
    Wang, Mengzhao
    Xu, Yan
    Huang, Wen-Tsung
    Su, Wu-Chou
    Gao, Bo
    Lee, Chee Khoon
    Fang, Jian
    Zhu, Xuehua
    Yang, Zhenfan
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    LUNG CANCER, 2025, 199
  • [32] Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer
    Rao, Ding-Yu
    Huang, De-Fa
    Si, Mao-Yan
    Lu, Hua
    Tang, Zhi-Xian
    Zhang, Zu-Xiong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [33] Profile of Reactive Estrogen Species in Women with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
    Bodor, J. N.
    Krzizike, D. D.
    Vanderveer, L.
    Eidbo, S.
    Zawislak, C. L.
    Ross, E. A.
    Andrews, A. J.
    Edelman, M. J.
    Treat, J.
    Clapper, M. L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S75 - S75
  • [34] Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Calvo, Emiliano
    Lee, Jong-Seok
    Kim, Sang-We
    Moreno, Victor
    deCastro Carpeno, Javier
    Weilert, Doris
    Laus, Gianluca
    Mann, Helen
    Vishwanathan, Karthick
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1099 - 1109
  • [35] Leptomeningeal carcinomatosis from EGFR-mutated non-small cell lung cancer
    Iuchi, T.
    Shingyoji, M.
    Setoguchi, T.
    Yoshida, Y.
    Ashinuma, H.
    Hasegawa, Y.
    Sakaida, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [37] Managing Acquired Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Forde, Patrick M.
    Ettinger, David S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 528 - 532
  • [38] Critical points in the management of EGFR-mutated non-small cell lung cancer
    Casaluce, Francesca
    Gridelli, Cesare
    JOURNAL OF THORACIC DISEASE, 2022, 14 (06) : 1748 - 1752
  • [39] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [40] Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
    Shepherd, Annemarie F.
    Preeshagul, Isabel R.
    Shaverdian, Narek
    Wu, Abraham J.
    Gelblum, Daphna Y.
    Gomez, Daniel R.
    Rimner, Andreas
    Simone, Charles B., II
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (23)
12345